References
- Anderson GL, McIntosh M, Wu L, et al (2010). Assessing lead time of selected ovarian cancer biomarkers. a nested casecontrol study. J Natl Cancer Inst, 102, 26-38. https://doi.org/10.1093/jnci/djp438
- Arakawa Y, Tachibana O, Hasegawa M, et al (2005). Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol, 109, 294-8. https://doi.org/10.1007/s00401-004-0956-6
- Bai C, Connolly B, Metzker ML, et al (2000). Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a fourgene cluster. Proc Natl Acad Sci, 97, 1230-5. https://doi.org/10.1073/pnas.97.3.1230
- Bamias G, Siakavellas SI, Stamatelopoulos KS, et al (2008). Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol, 129, 249-55. https://doi.org/10.1016/j.clim.2008.07.014
- Chen G, Luo D (2008). Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India, 21, 275-8.
- Chen G, Luo DZ, Wang Y (2007). Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma. Zhonghua Binglixue Zazhi, 36, 113-7.
- Chen L, Tian X, Li W, et al (2009). Expressions of Fas/DcR3 and RGD-FasL mediated apoptosis in pituitary adenomas. Neurol India, 57, 28-30. https://doi.org/10.4103/0028-3886.48808
- Connor JP, Felder M (2008). Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol, 111, 330-5. https://doi.org/10.1016/j.ygyno.2008.07.012
- Gill RM, Hunt JS (2004). Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis. Am J Pathol, 165, 309-17. https://doi.org/10.1016/S0002-9440(10)63298-1
- Hsu TL, Wu YY, Chang YC, et al (2005). Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol, 175, 5135-45. https://doi.org/10.4049/jimmunol.175.8.5135
- Li H, Zhang L, Lou H, et al (2005). Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol, 124, 282-7. https://doi.org/10.1309/XK594E4B5WU82QR6
- Li W, Zhang C, Chen C, et al (2007). Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. Cell Mol Immunol, 4, 455-60.
- Longley DB, Allen WL, McDermott U, et al (2004). The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptpsis in response to antimeabolites, 10, 3562-71. https://doi.org/10.1158/1078-0432.CCR-03-0532
- Macher-Goeppinger S, Aulmann S, Wagener N, et al (2008). Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia, 10, 1049-56. https://doi.org/10.1593/neo.08626
- Mueller AM, Pedre X, Killian S, et al (2009). The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol, 209, 57-64. https://doi.org/10.1016/j.jneuroim.2009.01.024
- Ohshima K, Haraoka S, Sugihara M, et al (2000). Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer letters, 160, 89-97. https://doi.org/10.1016/S0304-3835(00)00567-X
- Pitti RM, Marsters SA, Lawrence DA, et al (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature, 396, 699-703. https://doi.org/10.1038/25387
- Schwendel A, Richard F, Langreck H, et al (1998). Chromosome alterations in breast cancer carcinomas. frequent involvement of DNA losses including chromosomes 4q and 21q. Br J cancer, 78, 806-11. https://doi.org/10.1038/bjc.1998.583
- Shen HW, Gao SL, Wu YL, et al (2005). Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol, 11, 5926-30. https://doi.org/10.3748/wjg.v11.i38.5926
- Shi G, Wu Y, Zhang J, Wu J (2003). Death decoy receptor TR6/ DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol, 171, 3407-14. https://doi.org/10.4049/jimmunol.171.7.3407
- Takahama Y, Yamada Y, Emoto K (2002). The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer, 5, 61-8. https://doi.org/10.1007/s101200200011
- Wu Y, Han B, Sheng H, et al (2003). Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer, 105, 724-32. https://doi.org/10.1002/ijc.11138
- Yang CR, Hsieh SL, Teng CM, et al (2004). Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res, 64, 1122-9. https://doi.org/10.1158/0008-5472.CAN-03-0609
- You RI, Chang YC, Chen PM, et al (2008). Apoptosis of dendritic cell induced by decoy receptor 3(DcR3). Blood, 111, 1480-8.
Cited by
- Continuous Transarterial Infusion Chemotherapy with Gemcitabine and 5-Fluorouracil for Advanced Pancreatic Carcinoma vol.13, pp.6, 2012, https://doi.org/10.7314/APJCP.2012.13.6.2669
- Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo vol.32, pp.3, 2013, https://doi.org/10.3892/ijmm.2013.1437
- Overexpression of DcR3 and Its Significance on Tumor Cell Differentiation and Proliferation in Glioma vol.2014, pp.1537-744X, 2014, https://doi.org/10.1155/2014/605236
- Identification of Genomic Alterations in Pancreatic Cancer Using Array-Based Comparative Genomic Hybridization vol.9, pp.12, 2014, https://doi.org/10.1371/journal.pone.0114616